RTW Investments, LP and its Managing Partner Roderick Wong filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 5,820,891 shares of Larimar Therapeutics, Inc. common stock, representing 5.6% of the class, as of September 30, 2026.

Key Highlights

  • Reporting persons: RTW Investments, LP (a Delaware limited partnership and investment adviser) and Roderick Wong, M.D., its Managing Partner and Chief Investment Officer, filed jointly.
  • Shares beneficially owned: Each reporting person reported beneficial ownership of 5,820,891 shares of Larimar Therapeutics common stock, par value $0.001.
  • Ownership percentage: The 5,820,891 shares represent 5.6% of the class, calculated based on 103,882,937 shares outstanding as of August 2, 2026.
  • Voting and dispositive power: Both RTW Investments and Dr. Wong reported 0 sole voting power and 0 sole dispositive power; shared voting and shared dispositive power each equal 5,820,891 shares.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Shares held through funds: The shares are directly held by the RTW Funds, which have the right to receive dividends or proceeds from the sale of the reported shares, according to the filing.

RTW Investments and Roderick Wong Report Combined 5.6% Position in Larimar Therapeutics

According to the Schedule 13G filed November 16, 2026, RTW Investments, LP and Roderick Wong, M.D. together reported beneficial ownership of 5,820,891 shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) common stock. The filing identifies RTW Investments as a Delaware limited partnership that serves as investment adviser to certain funds referred to in the document as the "RTW Funds," which directly hold the reported shares. Dr. Wong is identified as the Managing Partner and Chief Investment Officer of RTW Investments.

The filing states that neither reporting person holds sole voting or sole dispositive power over any of the reported shares. Instead, both RTW Investments and Dr. Wong each report shared voting power and shared dispositive power of 5,820,891 shares. The percentage of class, 5.6%, was calculated using 103,882,937 shares outstanding as of August 2, 2026, as reported in Larimar Therapeutics' Quarterly Report on Form 10-Q filed with the SEC on August 4, 2026, according to the filing.

The filing includes a certification stating that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." The business address of each reporting person is listed as 40 10th Avenue, Floor 7, New York, New York 10014. A Joint Filing Agreement is listed as Exhibit 99.1.

What Was Disclosed

RTW Investments, LP and Roderick Wong, M.D. filed a Schedule 13G disclosing combined beneficial ownership of 5,820,891 shares, or 5.6%, of Larimar Therapeutics common stock, with all voting and dispositive power held on a shared basis as of September 30, 2026.